Fig. 5

FKBP1B and PAX9 methylation analysis in primary tumors and survival analysis. A The methylation rates were evaluated in clinical samples from different cohorts through MSP (methylation-specific PCR). For each sample, the presence of a product in lane M was considered as methylated DNA, while the product amplification in lane U was considered as non-methylated. Negative and positive controls for each reaction corresponded to DNA from PBMCs and in vitro methylated DNA, respectively. Representative MSPs of candidate genes are shown. B Samples 78, 79, 80, 82 and 140 showed methylation for FKBP1B, C and samples 152, 153 and 155 showed methylation for PAX9. Kaplan–Meier comparison in terms of overall survival (OS) between cisplatin response and PAX9 methylation in 21 patients with platinum-resistant ovarian cancer treated. Qualitative and quantitative methylation comparisons correspond to D and E, respectively. Log-rank tests were used for comparisons, and p values < 0.05 indicated a significant change in OS. We employed a Kaplan–Meier plotter tool to compare PAX9 expression versus OS and progression-free survival (PFS) (F, G) in 505 and 475 selected TCGA patients, respectively. A log-rank test was applied for comparisons, and p values < 0.05 indicated a significant change in OS